
$MRNA is up over 70% after becoming one of the first companies ever to deliver a positive Phase 3 result for a personalized cancer vaccine.
Treatment is built around each patient’s own tumor and when combined with KEYTRUDA it reduced the risk of melanoma returning or spreading.